Market Outline:
The 9MM Duchenne Muscular Dystrophy (DMD) Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during estimated year i.e. 2023 and expected to grow at a significant CAGR XX% over the projected period. And by the end of 2033, the market is expected to touch USD XX Million.
Duchenne muscular dystrophy is a genetic disease causing progressive muscle weakness and degeneration. There are more than 30 types of muscular dystrophies exits, this form capturing around half of the all muscular dystrophy cases.
Disease Burden Analysis:
- Global prevalence indicated around 10 cases of DMD occur in every group of 100,000 people.
- Nearly 250,000 people in United States carry some form of muscular dystrophy and prevalent pool in United States estimated around 52,000 suffering from DMD.
Report Insights:
- More than 300 clinical trials, United States is the dominated region
- Huge unmet need exists
- 10-15 molecules might witness the market by 2030 during forecast period
- CSP Analytics Solutions provided the clinical mapping of key pipeline molecules
The 9MM Duchenne Muscular Dystrophy (DMD) market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during estimated year i.e. 2023 and expected to grow at a significant CAGR % over the projected period. And by 2033, the market is expected to touch USD XX Million.
Market Segmentation Analysis by:
- By Drug Type:
- Corticosteroids
- Immunosuppressants
- Genetic therapy
- Exon skipping
- Ataluren (PTC124)
- Utrophin
- Others
- By Disease Stage:
- Early Stage
- Intermediate Stage
- Advanced Stage
- By End User:
Market Dynamics: Explored in report
- Surging Prevalence of DMD
- Growing Clinical Trial Activities
- Huge Market Unmet Need
- Favourable Drug Reimbursement Policies
Market Challenges: Explored in report
- Lack of Efficacious Treatment Option
- Cost of Treatment
- Reimbursement Driven Treatment
- Underdiagnoses in Emerging Market
Regional Outlook: Report has fragmented the total market in five regions such as US, 5-Europe, China, Japan, India and RoW (Rest of world).
Each mapped region has been examined at granular level based on certain parameters:
- United States
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
- 5-Europe
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
- China
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
- India
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
- Japan
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
- Rest of the World
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
Competitive Landscape: Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
Companies Profile:
- Sarepta Therapeutics, Inc.
- PTC Therapeutics, Inc.
- NS Pharma, Inc.
- Jerry R. Mendell
- GlaxoSmithKline
- ENCell
- REGENXBIO Inc.
- RSPR Pharma AB
- Summit Therapeutics
- BioMarin Pharmaceutical
- Phrixus Pharmaceuticals, Inc.
- Daiichi Sankyo Co., Ltd.
- Akashi Therapeutics
- Capricor Inc.
- Solid Biosciences Inc.
- Others
Molecules Investigated in the Report:
- rAAVrh74.MCK.Micro-Dystrophin
- IGF-1
- GSK2402968
- EN001
- RGX-202 Gene Therapy
- CRD007
- P-188 NF
- SGT-003 Gene Therapy
- Others
Reason to buy this report:
- Fostering Understanding on Duchenne Muscular Dystrophy (DMD) market
- In Order to Understand the Market Potential
- Opportunity Analysis (exist in the market for players)
- Clinical Developments in the market
- To Know Current and Future Market Trends
- Key Players and their Key Strategic Move
